DK3160956T3 - Inhibitorer af lysin-specifik demethylase-1 - Google Patents
Inhibitorer af lysin-specifik demethylase-1 Download PDFInfo
- Publication number
- DK3160956T3 DK3160956T3 DK15811526.1T DK15811526T DK3160956T3 DK 3160956 T3 DK3160956 T3 DK 3160956T3 DK 15811526 T DK15811526 T DK 15811526T DK 3160956 T3 DK3160956 T3 DK 3160956T3
- Authority
- DK
- Denmark
- Prior art keywords
- lysine
- inhibitors
- specific demethylase
- demethylase
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018365P | 2014-06-27 | 2014-06-27 | |
| PCT/US2015/038089 WO2015200843A1 (en) | 2014-06-27 | 2015-06-26 | Inhibitors of lysine specific demethylase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3160956T3 true DK3160956T3 (da) | 2020-08-31 |
Family
ID=54938856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15811526.1T DK3160956T3 (da) | 2014-06-27 | 2015-06-26 | Inhibitorer af lysin-specifik demethylase-1 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10011583B2 (da) |
| EP (1) | EP3160956B1 (da) |
| JP (2) | JP6587241B2 (da) |
| KR (1) | KR102438302B1 (da) |
| CN (1) | CN106660987B (da) |
| AU (2) | AU2015279591A1 (da) |
| BR (1) | BR112016030697B1 (da) |
| CA (1) | CA2953810C (da) |
| CL (1) | CL2016003350A1 (da) |
| CO (1) | CO2017000362A2 (da) |
| CY (1) | CY1123475T1 (da) |
| DK (1) | DK3160956T3 (da) |
| EA (1) | EA030946B1 (da) |
| EC (1) | ECSP17005635A (da) |
| ES (1) | ES2812626T3 (da) |
| HR (1) | HRP20201337T1 (da) |
| HU (1) | HUE050564T2 (da) |
| IL (1) | IL249733B (da) |
| LT (1) | LT3160956T (da) |
| MX (1) | MX2017000179A (da) |
| PL (1) | PL3160956T3 (da) |
| PT (1) | PT3160956T (da) |
| RS (1) | RS60658B1 (da) |
| SG (2) | SG10201911220TA (da) |
| SI (1) | SI3160956T1 (da) |
| WO (1) | WO2015200843A1 (da) |
| ZA (1) | ZA201700069B (da) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| HUE050564T2 (hu) | 2014-06-27 | 2020-12-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
| EP3164380B1 (en) * | 2014-07-03 | 2022-02-09 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| KR102626978B1 (ko) | 2015-02-12 | 2024-01-18 | 이마고 바이오사이언시즈 인코포레이티드 | 질환 치료를 위한 kdm1a 저해제 |
| EP3307909A1 (en) | 2015-06-12 | 2018-04-18 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
| EP3430015A1 (en) | 2016-03-16 | 2019-01-23 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN111194306B (zh) | 2016-08-16 | 2023-05-16 | 伊美格生物科学公司 | 用于制备kdm1a抑制剂的方法和过程 |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| JP2020121925A (ja) * | 2017-04-10 | 2020-08-13 | 三井化学アグロ株式会社 | ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物 |
| WO2018190324A1 (ja) * | 2017-04-10 | 2018-10-18 | 三井化学アグロ株式会社 | ピリドン化合物を有効成分として含有する抗真菌剤およびその使用方法 |
| WO2018190323A1 (ja) * | 2017-04-10 | 2018-10-18 | 三井化学アグロ株式会社 | ピリドン化合物と有害生物防除剤を含有する有害生物防除組成物および有害生物の防除方法 |
| CN110996949A (zh) | 2017-08-03 | 2020-04-10 | 奥瑞泽恩基因组学股份有限公司 | 用于治疗行为改变的方法 |
| WO2019182960A1 (en) * | 2018-03-21 | 2019-09-26 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
| KR20210008064A (ko) | 2018-05-11 | 2021-01-20 | 이마고 바이오사이언시즈 인코포레이티드 | 질환의 치료를 위한 kdm1a 저해제 |
| CA3130638A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| EP4319732A1 (en) | 2021-04-08 | 2024-02-14 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2599925A1 (en) * | 2005-03-14 | 2006-09-21 | Merck & Co., Inc. | Cgrp receptor antagonists |
| MX2008015648A (es) * | 2006-06-21 | 2009-01-09 | Du Pont | Pirazinonas como inhibidores de proliferacion celular. |
| JP5140154B2 (ja) | 2007-06-27 | 2013-02-06 | アストラゼネカ・アクチエボラーグ | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| BR112014031068A2 (pt) * | 2012-06-12 | 2017-06-27 | Abbvie Inc | derivados piridinona e piridazinona |
| WO2015089192A1 (en) | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
| HUE050564T2 (hu) | 2014-06-27 | 2020-12-28 | Celgene Quanticel Res Inc | Lizinspecifikus demetiláz-1 inhibitorai |
-
2015
- 2015-06-26 HU HUE15811526A patent/HUE050564T2/hu unknown
- 2015-06-26 RS RS20200980A patent/RS60658B1/sr unknown
- 2015-06-26 DK DK15811526.1T patent/DK3160956T3/da active
- 2015-06-26 PL PL15811526T patent/PL3160956T3/pl unknown
- 2015-06-26 CN CN201580046216.4A patent/CN106660987B/zh active Active
- 2015-06-26 BR BR112016030697-0A patent/BR112016030697B1/pt not_active IP Right Cessation
- 2015-06-26 MX MX2017000179A patent/MX2017000179A/es active IP Right Grant
- 2015-06-26 EP EP15811526.1A patent/EP3160956B1/en active Active
- 2015-06-26 PT PT158115261T patent/PT3160956T/pt unknown
- 2015-06-26 SG SG10201911220TA patent/SG10201911220TA/en unknown
- 2015-06-26 SI SI201531328T patent/SI3160956T1/sl unknown
- 2015-06-26 CA CA2953810A patent/CA2953810C/en active Active
- 2015-06-26 AU AU2015279591A patent/AU2015279591A1/en not_active Abandoned
- 2015-06-26 JP JP2016575362A patent/JP6587241B2/ja active Active
- 2015-06-26 EA EA201692513A patent/EA030946B1/ru unknown
- 2015-06-26 US US15/322,277 patent/US10011583B2/en active Active
- 2015-06-26 LT LTEP15811526.1T patent/LT3160956T/lt unknown
- 2015-06-26 WO PCT/US2015/038089 patent/WO2015200843A1/en active Application Filing
- 2015-06-26 ES ES15811526T patent/ES2812626T3/es active Active
- 2015-06-26 SG SG11201610866PA patent/SG11201610866PA/en unknown
- 2015-06-26 KR KR1020177000953A patent/KR102438302B1/ko active IP Right Grant
-
2016
- 2016-12-22 IL IL249733A patent/IL249733B/en active IP Right Grant
- 2016-12-27 CL CL2016003350A patent/CL2016003350A1/es unknown
-
2017
- 2017-01-04 ZA ZA2017/00069A patent/ZA201700069B/en unknown
- 2017-01-16 CO CONC2017/0000362A patent/CO2017000362A2/es unknown
- 2017-01-26 EC ECIEPI20175635A patent/ECSP17005635A/es unknown
-
2018
- 2018-05-29 US US15/991,222 patent/US10597376B2/en not_active Expired - Fee Related
-
2019
- 2019-05-03 JP JP2019087186A patent/JP6851418B2/ja active Active
- 2019-11-07 AU AU2019261771A patent/AU2019261771B2/en not_active Ceased
-
2020
- 2020-02-03 US US16/780,704 patent/US11028066B2/en active Active
- 2020-08-14 CY CY20201100759T patent/CY1123475T1/el unknown
- 2020-08-26 HR HRP20201337TT patent/HRP20201337T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3377059T3 (da) | Hæmmere af cxcr2 | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3207043T6 (da) | Dihydropyrrolopyridin-inhibitorer af ror-gamma | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| BR112017000042A2 (pt) | inibidores de desmetilase-1 lisina-específica | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3220891T3 (da) | Sublingual formulering af riluzol | |
| DK3132009T3 (da) | Fremgangsmåde | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin |